Cancer News and Research

Latest Cancer News and Research

Loyola's SSOM receives $100,000 grant for research into pediatric leukemia

Loyola University Chicago Stritch School of Medicine (SSOM) today received a $100,000 grant to support research to treat an aggressive form of pediatric leukemia.

4 Oct 2011

Researchers identify new enzyme function that may protect against anemia

Researchers at St. Michael's Hospital have discovered a new function for an enzyme that may protect against organ injury and death from anemia.

4 Oct 2011

Study: Fair-skinned people may need to take vitamin D supplements

Fair-skinned people who burn quickly in the sun may need to take supplements to ensure they get the right amount of vitamin D, new research finds.

4 Oct 2011

Discovery of ‘alarm-clock’ gene

Researchers led by Indian-American scientist, Satchidananda Panda at the Salk Institute for Biological Studies in La Jolla, Calif., said the gene is responsible for starting the body’s biological clock from its restful state every morning. They add that this may open avenues in research in insomnia or sleeplessness, aging and chronic illnesses.

3 Oct 2011

Brave breast cancer survivors on camera – scars and all

David Jay is a fashion photographer who has spent years capturing images of perfectly formed beautiful women. About five years ago, he began shooting young breast cancer survivors after his girlfriend's twin sister was diagnosed with the disease in her late 20s. His motive was to raise awareness that breast cancer can ravage young women as well as old.

3 Oct 2011

Novel drug shows promise for MLL leukemia

According to British scientists a potential new drug from GlaxoSmithKline could treat mixed-lineage leukemia (MLL). MLL is the most common form of leukemia in babies. The study appeared in the journal Nature where scientists from the British drugmaker collaborating with the charity Cancer Research UK (CRUK) and Cellzome AG found that the experimental drug, called I-BET151.

3 Oct 2011

Adaptimmune announces new board appointments as clinical programmes get underway

Adaptimmune, the T cell therapy company pioneering enhanced T cell receptor-driven T cells for the treatment of cancer and infectious disease, announces two new Board appointments with immediate effect. Dr Jonathan Knowles joins the Board as a non-executive director and Dr Helen Tayton-Martin, Adaptimmune’s Chief Operating Officer, becomes an executive director.

3 Oct 2011

Despite increase in cases, awareness of male breast cancer is low

Awareness of male breast cancer is low and most men do not even know they are at risk despite an increase in cases, reveals new research from the University of Leeds.

3 Oct 2011

EntreMed announces data from ENMD-2076 Phase 2 study in platinum-resistant ovarian cancer

EntreMed, Inc., a clinical stage pharmaceutical company developing therapeutics for the treatment of cancer today announced the final data for the primary endpoint of progression free survival rate at 6 months for its Phase 2 study with ENMD-2076 in platinum-resistant ovarian cancer patients.

3 Oct 2011

Perinatal exposure to BPA affects mammary hormone response

A recent study accepted for publication in Molecular Endocrinology, a journal of The Endocrine Society, found that perinatal exposure to environmentally relevant doses of bisphenol A (BPA) alters long-term hormone response and breast development in mice that may increase the propensity to develop cancer.

3 Oct 2011

Potential new drug could treat mixed-lineage leukaemia

A team lead by Cancer Research UK scientists have shown that a potential new drug could treat mixed-lineage leukaemia (MLL), the most common form of leukaemia in babies, according to a study published in Nature today.

3 Oct 2011

GeoVax completes enrollment for HIV/AIDS vaccine Phase 2a clinical trial

GeoVax Labs, Inc., an Atlanta-based biopharmaceutical firm developing vaccines to prevent and fight Human Immunodeficiency Virus (HIV) infections, announced today the completion of enrollment for a Phase 2a clinical trial testing its HIV/AIDS vaccine.

3 Oct 2011

First Edition: October 3, 2011

Today's headlines include stories previewing how health policy issues will fit into the Supreme Court's new term.

3 Oct 2011

Alkermes initiates ALKS 37 phase 2b study in opioid-induced constipation

Alkermes plc today announced the initiation of a phase 2b study of ALKS 37, an orally active, peripherally restricted opioid antagonist for the treatment of opioid-induced constipation.

3 Oct 2011

La Jolla Institute scientist identifies previously unknown T cell interaction

Most of the time, the immune system is the body's protector, warding off invading viruses and bacteria before they can lead to infection and disease. But in autoimmune diseases, the immune system does an about face, turning on the body and attacking normal cells.

3 Oct 2011

New research uses Tilman model to study metastasis of prostate cells into bone

The invasion of a new species into an established ecosystem can be directly compared to the steps involved in cancer metastasis. New research published in BioMed Central's open access journal Theoretical Biology and Medical Modelling uses the Tilman model of competition between invasive species to study the metastasis of prostate cells into bone.

3 Oct 2011

Baptist Hospital selects RayStation treatment planning system

RaySearch Laboratories AB has received an order for its RayStation treatment planning system from Baptist Hospital of Miami.

3 Oct 2011

Elekta sells Anatomic Pathology Information System business to Sunquest

Elekta AB today announced it has divested its Anatomic Pathology Information System business, marketed under the brand name PowerPath, a software line that manages workflow for laboratories offering surgical pathology, cytology, dermatopathology and autopsy services.

From Elekta 3 Oct 2011

Study compares treatment plans for CyberKnife treatment delivery system

Radiosurgery is a non-invasive medical procedure in which focused beams of high-energy X-rays target tumors and other abnormalities in the body. A single large dose of radiation is capable of ablating a lesion that might not be amenable to surgical removal. However, some radiosurgery systems, such as the CyberKnife (CK), can be relatively time-consuming because the treatment planning requires the delivery of up to several hundred cone-shaped beams to adequately cover an irregularly shaped tumor.

3 Oct 2011

Hassenfeld family, NYU Langone unveil $50M gift to create new pediatric hospital

NYU Langone Medical Center and the Hassenfeld family unveiled a $50 million gift today that will create a comprehensive pediatric hospital at NYU Langone Medical Center.

3 Oct 2011